The new Merck drug, known as Victrelis, significantly increases the cure rate and shortens treatment for some patients diagnosed with the chronic liver disease. The decision by the U.S. Food and Drug Administration to approve Victrelis was widely expected following a positive recommendation from an outside advisory panel last month.
Merck has not yet disclosed pricing for Victrelis, which is used in combination with long-acting interferon and ribavirin.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts